NEW YORK (GenomeWeb) – Foundation Medicine announced today that it has formed a three-way collaboration with Horizon Healthcare Services and Clinical Outcomes Tracking and Analysis (COTA) to study the clinical and cost benefits of Foundation's precision medicine technology in treating metastatic non-small cell lung cancer (NSCLC).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.